CD37 and non-Hodgkin lymphoma: CD37, like its “rival” CD20, is absent on early progenitor cells or terminally differentiated plasma cells [4,8] and relatively highly expressed on malignant B cells, which makes it an ideal targets for the therapy of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) [4,71].